Vielight RX Plus for Quicker COVID-19 Recovery Approved by Health Canada

Vielight has announced that its RX Plus device which uses near-infrared light technology to accelerate the recovery of COVID-19 in adults has been approved by Health Canada. The approval represents the first medical device cleared by Health Canada for quicker recovery from acute COVID-19 infection. The non-invasive, portable Vielight RX Plus treatment does not require a prescription.

Vielight RX Plus is a non-invasive photobiomodulation (PBM) device intended for COVID-19 patients, especially those experiencing acute symptoms within seven days of onset symptoms. The Health Canada approval was supported by a randomized clinical trial involving 295 subjects conducted by Vielight with independent testing labs as well as a contract research organization and other board-certified clinical investigators.

The RX Plus device will retail at $549 and is expected to be available within three months for purchase by consumers, practitioners and doctors.

Related: DRx SpectraLite EyeCare Max Pro Provides Next Generation LED Eye Treatment

“This Health Canada approval is the culmination of our deep commitment to safety and effectiveness,” said Nazanin Hosseinkhah, Ph.D., who managed the COVID-19 study together with clinical partners. “Even as interest in photobiomodulation rapidly grows, we are dedicated to reassuring consumers that this transformative technology, soon to be accessible to them, is validated by formal research.”

“This approval is a major endorsement for photobiomodulation,” said Michael R Hamblin, Ph.D., formerly Associate Professor at Harvard Medical School and now Distinguished Visiting Professor at the University of Johannesburg. “The body of published research on PBM and coronavirus infection etiology has suggested that PBM may be effective in inhibiting the harmful effects of coronaviruses. It could boost the activities of the immune system while managing the risk of inflammation. PBM is also recognized for its healing properties, which may aid recovery.”

“If the COVID-19 pandemic has taught us anything, it’s that people prefer to recover at home,” said Lew Lim, Ph.D., Founder & CEO of Vielight. “Our Vielight RX Plus technology strengthens and protects our immune and respiratory systems while suppressing the replication of coronaviruses. We are pleased that Health Canada has granted approval of our technology so we can expand access to this treatment to the thousands of people who still contract COVID-19 every day. With the advantages of strong in-house research and engineering, coupled with knowledge gained from this clinical trial, we will soon be commencing a new clinical trial to test the effectiveness of our PBM technology for long COVID.”